The Committee on Energy and Commerce is the oldest standing legislative committee (established 1795) in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee. The Energy and Commerce Committee is at the forefront of all issues and policies powering America’s economy, including our global competitive edge in energy, technology, and health care. The committee is led by E&C Chairman Brett Guthrie (KY-02) and E&C Ranking Member Frank Pallone (NJ-06). The Subcommittee on Environment is led by Chairman Buddy Carter (GA-01) and Ranking Member Kathy Castor (FL-14).
I want to welcome everyone to today's hearing on the over-the-counter monograph
drug user fee program referred to as AMUFA. I'm especially pleased that we are talking about the
reauthorization of this program as almost five years to the date the initial bill sponsored by
my good friend from Ohio Representative Latta as well as one of Georgia's finest Senator Johnny
Isaacson was signed into law by President Trump in March of 2020. The enactment of this program
reformed and modernized the regulation of OTC monograph drugs and authorized the FDA to assess
and collect user fees dedicated to OTC monograph drug activities. Industry and public health
stakeholders supported these reforms which have provided FDA with additional resources and tools
to streamline the monograph process to increase access to quality commonly used drugs and self-care
products for the American consumer. This program is designed to improve innovation while maintaining
the FDA gold standard of safety. The current legislative authority for AMUFA expires September
30, 2025. Again September 30, 2025 at which point new legislation will be required to reauthorize
the over-the-counter monograph user fee program for another five-year term. Over-the-counter
medications are widely used to treat common ailments such as colds, headaches, and seasonal
allergies. In fact nearly nine out of every 10 Americans use OTC medications regularly and trust
these affordable remedies to get well and stay healthy. Safe, reliable, and affordable OTC drugs
allow consumers to treat common ailments at home usually without visiting a health care provider
saving the health care system billions annually. A particular note is a company named Simrise.
They own and operate a manufacturing plant in Georgia's first congressional district that I have
the honor and privilege of representing. Simrise manufactures aroma molecules and fragrance
ingredients which are used in various consumer products across a number of product categories.
They also manufacture two of the key UV filters that are commonly used in many OTC sunscreens on
the market today. Sadly Simrise Colonel's Island plant experienced a serious fire in 2022. Simrise
made the strategic decision to reinvest in the site and restore its capacity in my community
at a time when other companies were leaving. They successfully completed renovations and today
the plant is again fully operational back at its pre-fire capacity. This is a real success story
and we are grateful for their commitment to Georgia. We are also fortunate to have Mr. Kevin
Menzel before our committee today. Mr. Menzel is president of Focus Consumer Health Care which is
a wholly owned subsidiary of Kobayashi Healthcare. Kobayashi was founded as a family company in 1886
in Japan. They established a presence in the United States in 1998 and maintain manufacturing
and operations in Dalton, Georgia employing 270 people with products ranging from OTC medicines
and supplements to recreational products like hot hands hand warmers. Georgia's pro-business
climate and infrastructure make it an ideal location for companies such as Kobayashi and
as Kobayashi. In fact just recently Kobayashi began expanding its U.S. manufacturing footprint
even further with a significant announced investment in Georgia doubling capacities
to support ongoing growth and expand employment. Success stories such as Simrise and Kobayashi
highlight why it's critical for this subcommittee to reauthorize the over-the-counter monograph drug
user fee program in a timely manner. This program demonstrated the ability to bring more jobs back
to America while increasing access to safe reliable and affordable OTC drugs. I look forward
to hearing from our witnesses today and working with my colleagues on both sides of the aisle
to reauthorize this program on time and through regular order.